目的:探讨米非司酮治疗子宫肌瘤50例的临床疗效.方法:选择2009年10月～2010年10月确诊为子宫肌瘤的患者50例,给予口服米非司酮治疗.B超检测子宫及子宫肌瘤的大小,实验室检测血清激素水平,观察服药后的不良反应.结果:治疗后子宫及子宫肌瘤的体积均明显缩小,差异有统计学意义(P<0.05);治疗后卵泡刺激素(FSH)、促黄体生成激素(LH)、雌激素(E2)、孕酮(P)水平较用药前下降,差异均有统计学意义(均P<0.05),催乳素(PRL)和雄激素(T)水平改善不明显,差异无统计学意义(P＞0.05).所有患者均未出现肝肾功能变化、体重增加、色素沉着、低血压等不良反应.随访48例,45例月经复潮,复潮患者中,27例子宫肌瘤无明显增大,有效率为60.0%.结论:米非司酮治疗子宫肌瘤效果好,不良反应少,有积极的临床价值.%Objective: To explore the clinical effect of Mifepristone in the treatment of 50 cases of patients with uterine fibroids.Methods: 50 cases of patients diagnosed with uterine fibroids from October 2009 to October 2010 were selected and given oral Mifepristone.B ultrasound was used to detect the sizes of uterine and uterine fibroids, and serum hormone levels and adverse reactions were observed.Results: After treatment, the sizes of uterine and uterine fibroids all decreased obviously with statistically significant differences (P＜0.05).After administration, average levels of FSH, LH, E2 and P all decreased which compared to those before administration with significant differences (P＜0.05), but PRL and T value change were not obvious (P＞0.05).Hepatorenal function change, weight gain, pigmentation, hypotension and other adverse reactions did not happen in patients.Among 48 cases of follow-up patients, menstruation again happened in 45 cases, of whom 27 cases had no obviously enlargement of uterine fibroids.The effective rate was 60.0％.Conclusion: The clinical effect of Mifepristone in the treatment of uterine fibroids is good with few adverse reactions and positive clinical value.
展开▼
